Adaptive Bio Launches T-Cell Based COVID-19 Tests

  • Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection. 
  • T-Detect is currently under review by the FDA for Emergency Use Authorization.
  • Separately, the Company also expanded its collaboration with Laboratory Corp. of America Holdings (NYSE: LH), which includes a commercial agreement for Adaptive's clonoSEQ and immunoSEQ assays, and a lab services agreement for Adaptive's recently launched T-Detect COVID test.
  • As part of the expanded pact, patients can now have blood collection for both the clonoSEQ and T-Detect COVID tests at any Lab Corp patient service centers.
  • Lab Corp will also offer immunoSEQ and immunoSEQ T-MAP COVID assays using Research Use Only test kits.
  • Price Action: LH is up 1.3% at $247.24, while ADPT is down 4.20% at $54.34 in market trading hours on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralCovid-19 tests
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!